Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page revision was updated to v3.6.6, replacing the previous v3.6.5, indicating an administrative update to the record. This does not reflect changes to the study details themselves.SummaryDifference0.0%

- Check20 days agoChange DetectedA line reading '2023 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, indicating NIH funding for the trial. This adds funding attribution to the study record.SummaryDifference0.0%

- Check34 days agoChange DetectedThe page's revision label updated from v3.6.4 to v3.6.5, indicating a minor update to the page revision history.SummaryDifference0.0%

- Check48 days agoChange DetectedThree site entries were edited to standardize their names by removing diacritics and minor punctuation: Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 253147; Hospital Da Crianca Santo Antonio /ID# 233249; and Fundacion Ctic - Centro De Tratamiento E Investigacion Sobre Cancer Luis Carlos /ID# 258131.SummaryDifference0.1%

- Check55 days agoChange DetectedAdds clarifications that Telisotuzumab Vedotin is investigational and outlines a 1:1 randomized design between Telisotuzumab Vedotin and Docetaxel, with about 768 participants across roughly 330 sites worldwide. Updates the study’s locations and related eligibility notes, replacing the prior enrollment figure (698) and adding new sites.SummaryDifference0.7%

- Check77 days agoChange DetectedThe revision label changed from v3.6.0 to v3.6.3, signaling a new software release for the page. This is a technical update rather than content changes.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.